CN107213176B - Hydrangea macrophylla leaf extract, and pharmaceutical composition, preparation method and application thereof - Google Patents
Hydrangea macrophylla leaf extract, and pharmaceutical composition, preparation method and application thereof Download PDFInfo
- Publication number
- CN107213176B CN107213176B CN201710448481.6A CN201710448481A CN107213176B CN 107213176 B CN107213176 B CN 107213176B CN 201710448481 A CN201710448481 A CN 201710448481A CN 107213176 B CN107213176 B CN 107213176B
- Authority
- CN
- China
- Prior art keywords
- extract
- hydrangea
- ethanol
- hydrangea macrophylla
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Abstract
The invention belongs to the field of traditional Chinese medicine and natural medicine pharmacy, and relates to a hydrangea macrophylla leaf extract, a pharmaceutical composition, a preparation method and application thereof. The invention aims to provide application of total phenolic acid extracts of hydrangea macrophylla leaves in preparation of medicines for treating thyroid cancer. The preparation method of the hydrangea leaf extract comprises the following steps: (1) pulverizing flos Impatientis leaf, and extracting with solvent; (2) filtering, and concentrating the filtrate for later use; (3) extracting the concentrated solution to obtain extract, adding water into the extract, and filtering to obtain filtrate; (4) adsorbing the filtrate with macroporous resin column, sequentially eluting with distilled water, 10-20% ethanol water solution, 20-30% ethanol, and 30-40% ethanol, collecting 30-40% ethanol eluate, concentrating, drying, pulverizing, and sieving to obtain hydrangea macrophylla leaf extract. The content of the total phenolic acid in the total phenolic acid extract of the hydrangea macrophylla leaves is up to 40 percent, and the quality is stable and controllable. The extract has definite therapeutic effect on thyroid cancer through in vivo and in vitro pharmacological tests on thyroid cancer.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicine and natural medicine pharmacy, and particularly relates to a hydrangea macrophylla leaf extract, a pharmaceutical composition, a preparation method and application thereof.
Background
Hydrangea (Hydrangea macrophylla) also called Hydrangea, Astrongym, Maackia cauliflora is a perennial herb of Hydrangea of Saxifragaceae. The original China mainland is in the south of the middle and lower reaches of the Yangtze river, Japan, and the like, has a long cultivation history in China, and is distributed in the south and north of China. The Chinese medicine dictionary records: bitter, slightly pungent, cold and slightly toxic. Its compound recipe can treat malaria and renal capsule wind. In recent years, many studies have been made by japanese scholars, and the active ingredients thereof have biological activities such as antiulcer and antiallergic activities. Background of thyroid cancer is a clinically common malignant tumor, and the incidence rate of thyroid cancer rapidly increases in recent 10 years (1). Recent data show that the incidence of thyroid cancer increases by around 5% per year (2). Although researchers believe that the incidence of the disease is increased in recent years due to the discovery of biomarkers such as thyroglobulin and antithyroid globulin antibodies and the improvement of clinical diagnosis technology, the diagnosis rate of thyroid cancer is improved, but the incidence rate of the thyroid cancer is increased by 0.9 percent every year. Thyroid cancer has 4 main pathological types: papillary Thyroid Carcinoma (PTC), Follicular Thyroid Carcinoma (FTC), medullary Carcinoma (MTC), and undifferentiated Carcinoma (ATC). PTC and FTC are Differentiated Thyroid Cancer (DTC), which accounts for 90-95% of Thyroid cancer. The treatment of most patients by the traditional method can obtain good curative effect. Thus, DTC patients reach 90% of their 20-year survival. However, there are still a small percentage of DTC patients who have distant metastasis and do not absorb radioactive iodine, and their 10-year survival rate is only 15-20% (3) due to the lack of effective treatment.
With the rapid development of thyroid cancer molecular biology research in recent years, many effective drug molecular action targets are successively discovered, and many effective targeted therapeutic drugs are developed based on these targets, wherein the targeted drugs sorafenib (sorafenib) and lenvatinib (lenvatinib) have been successfully marketed. The targeted therapy provides a new treatment means for refractory thyroid cancer, obviously improves the prognosis survival period of patients with advanced thyroid cancer, and has good development and application prospects. Although molecular targeted drugs have achieved great success, some patients have to reduce the dosage and even stop taking the drugs because some drugs have large and serious toxic and side effects, so that the due therapeutic effect cannot be achieved. Therefore, the development of new high-efficiency and low-toxicity therapeutic drugs is still the focus of thyroid cancer treatment.
At present, the leaves of Hydrangea (Hydrangea macrophylla) or the total phenolic acid extract thereof have no report of thyroid cancer resistance, and the literature reports of the production process of the Hydrangea total phenolic acid extract at home and abroad are blank.
Disclosure of Invention
The invention aims to provide a hydrangea macrophylla leaf extract and a preparation method and application thereof. In particular to the application of the total phenolic acid extract of hydrangea macrophylla leaf in the preparation of the medicine for treating thyroid cancer.
The hydrangea leaf extract is prepared by the following method, and the steps are as follows:
(1) pulverizing dried folium hydrangeae strigosae, soaking in ethanol water solution, and heating for extraction;
(2) filtering to obtain filtrate, concentrating, and keeping the concentrated solution;
(3) extracting the concentrated solution obtained in the step (2) with petroleum ether or n-hexane, then extracting with n-butanol, concentrating the n-butanol layer extract under reduced pressure to obtain extract, adding water to dissolve the extract, and performing suction filtration to obtain filtrate for later use;
(4) adsorbing the filtrate obtained in the step (3) by using a macroporous resin column, sequentially eluting by using distilled water, 10% v/v-20% v/v ethanol water solution, 20% v/v-30% v/v ethanol and 30% v/v-40% v/v ethanol, collecting 30% v/v-40% v/v ethanol eluate, concentrating, drying, crushing and sieving to obtain the hydrangea leaf extract.
The hydrangea leaf extract disclosed by the invention takes quercetin as a quantitative index, wherein the content of total phenolic acid is more than 40%, namely the hydrangea leaf extract disclosed by the invention is the total phenolic acid extract of hydrangea leaf.
In the technical scheme, the concentration of the ethanol aqueous solution in the step (1) is 60-90%, the material-liquid ratio is 1:5-20 by weight, the soaking time is 12-24 hours, and the ethanol aqueous solution is heated and refluxed for extraction for 2-3 times, and each time lasts for 2-3 hours.
In the technical scheme, the concentration in the step (2) is carried out until the relative density is 1.00-1.20.
In the technical scheme, the concentrated solution in the step (3) is extracted by petroleum ether or normal hexane and normal butanol for 2-3 times respectively, the dosage of organic solvent adopted in each extraction is extracted according to the weight ratio of the concentrated solution to the organic solvent of 0.5-1:1, the extract of the normal butanol extract is dissolved by adding water, and the extract is dissolved by adding distilled water according to the weight ratio of the extract to the distilled water of 1: 10-35.
Preferably, in the step (3), the concentrated solution is extracted by petroleum ether and n-butanol for 2-3 times respectively, the dosage of the organic solvent adopted in each extraction is the proportion of 0.5:1 of the weight ratio of the concentrated solution to the organic solvent, the n-butanol extract is dissolved by adding water, and the distilled water is added to dissolve the extract according to the proportion of 1:10-35 of the weight ratio of the extract to the distilled water.
In the technical scheme, the macroporous resin column in the step (4) is AB-8, HPD300, HPD400 or D101 type macroporous adsorption resin.
In the technical scheme, distilled water is eluted by 3-6 column volumes in the step (4), ethanol water solution with the concentration of 10% -v/v-20% v/v is eluted by 3-6 column volumes, and ethanol with the concentration of 30% -v/v-40% v/v is eluted by 3-10 column volumes.
In the technical scheme, the sample loading amount in the step (4) is carried out on a macroporous resin column according to the weight ratio of the medicinal materials to the resin of 1: 1-2.
In the technical scheme, the elution speed of the elution in the step (4) is 0.1-0.5L/h.
The total phenolic acid extract of the hydrangea macrophylla leaves prepared by the technical scheme comprises the steps of analyzing by T L C and HP L C, combining ESI-MS,1HNMR and13the CNMR spectrum data analysis verifies that the extract contains quercetin, and HP L C analysis result shows that most compounds in the extract are quercetin analogues (with similar ultraviolet absorption), so that the quercetin is used as a reference substance, and the content of the total phenolic acid is determined by adopting an ultraviolet spectrophotometry method.
Furthermore, experiments on the pharmacological action of the extract on the thyroid cancer in vitro and in vivo show that the total phenolic acid extract of hydrangea macrophylla has a dosage-dependent anti-tumor effect on medullary thyroid carcinoma in a subcutaneous tumor transplantation model of a human medullary thyroid carcinoma cell line. Cell level experiments show that the total phenolic acid extract of hydrangea macrophylla can inhibit the proliferation of human medullary thyroid carcinoma cell lines, has dosage and time dependence of inhibition effect, and has the effect of treating thyroid carcinoma. Therefore, the application of the total phenolic acid extract of hydrangea macrophylla is the application of the total phenolic acid extract of hydrangea macrophylla in preparing the medicine for treating thyroid cancer.
In order to utilize the application, the invention also provides a medicament prepared by taking the total phenolic acid extract of the hydrangea macrophylla leaves as a main active ingredient and adding pharmaceutically conventional auxiliary materials. For example, the preparation can be prepared into oral preparations or injection preparations. Specifically, the oral preparation can be made into tablet, capsule, granule, oral liquid, etc.; the injectable formulation may be an intravenous formulation.
The invention has the following beneficial effects:
1) provides a preparation method for extracting the total phenolic acid extract of the hydrangea macrophylla leaves for the first time.
2) The content of the total phenolic acid in the total phenolic acid extract of the hydrangea macrophylla leaf is up to 40 percent, and the quality is stable and controllable.
3) The total phenolic acid extract of the hydrangea macrophylla leaves disclosed by the invention has a definite treatment effect on thyroid cancer through in vivo and in vitro antithyroid cancer pharmacological tests.
4) The preparation method of the invention has the advantages of economic and simple process and is suitable for industrial mass production.
Drawings
FIG. 1 shows the inhibition effect of total phenolic acid extract of hydrangea macrophylla leaf on the proliferation of thyroid medullary carcinoma cell TT.
FIG. 2 shows the inhibitory effect of total phenolic acid extract from hydrangea macrophylla on the growth of medullary thyroid carcinoma tumor.
FIG. 3 shows the effect of total phenolic acid extract from hydrangea macrophylla on mouse body weight.
FIG. 4 shows the effect of total phenolic acid extract from hydrangea macrophylla leaves on tumor regrowth in mice.
Detailed Description
The present invention will be described in further detail below with reference to specific embodiments of examples, but the present invention is not limited thereto. And the content of total phenolic acid in the total phenolic acid extract of hydrangea macrophylla leaves prepared in the following examples is measured by ultraviolet spectroscopy.
Example A preparation of Total phenolic acid extract of hydrangea macrophylla leaf
2kg of dried medicinal materials of crushed hydrangea macrophylla leaves are added with 60% ethanol according to the weight ratio of the medicinal materials to ethanol solution of 1:5 to be soaked for 12 hours, then heated and refluxed to be extracted for 3 times, the extraction time of each time is 2h, 2h and 2h, three extraction solutions are combined, the solvent is filtered and recovered, the concentrated solution is concentrated to the relative density of 1.00 to 1.20, the concentrated solution is respectively extracted for three times by petroleum ether and n-butyl alcohol, the concentrated solution is extracted according to the weight ratio of the concentrated solution to the solvent of 1:1, three n-butyl alcohol extraction solutions are combined and concentrated to obtain an n-butyl alcohol extract of 67.8g, the n-butyl alcohol extract is dissolved by distilled water of 1.5L, the filtrate is adsorbed on an AB-8 type macroporous resin column of 2kg to be adsorbed repeatedly for three times, firstly, the distilled water of 3 times of the column volume and 10% ethanol solution of 3 times of the column volume are used for eluting impurities, 30% ethanol solution of 5 times of the column volume is used for eluting, 30% of ethanol eluent of 30% is collected and concentrated to obtain the total phenolic acid extract of the hydra.
Example preparation of Total phenolic acid extract of Erbaxian flower leaves
The method comprises the steps of adding 70% ethanol into 2kg of dried medicinal materials of crushed hydrangea macrophylla leaves according to the weight ratio of the medicinal materials to ethanol solution of 1:10 to soak for 12 hours, then heating and refluxing for 3 times, combining three extracting solutions for 2h, 2h and 2h each time, filtering, recovering a solvent, concentrating until the relative density is 1.00-1.20, extracting concentrated solution with petroleum ether and n-butyl alcohol for three times respectively, extracting according to the weight ratio of the concentrated solution to the solvent of 1:1, combining three n-butyl alcohol extracting solutions, concentrating to obtain an n-butyl alcohol extract of 85.3g, dissolving the n-butyl alcohol extract with distilled water of 2.8L, filtering, adsorbing filtrate to an HPD300 type macroporous resin column of 4kg for three times, eluting with distilled water of 4 times of the column volume and 20% ethanol solution of 5 times of the column volume for the first time to remove impurities, collecting 40% ethanol eluting solution of 40% of 10 times of the column volume, and concentrating to obtain the total hydrangea macrophenolic acid extract of 5.5.5 g.
Example preparation of Total phenolic acid extract of Sabaxian flower leaves (III)
The method comprises the steps of adding 90% ethanol into 2kg of dried medicinal materials of crushed hydrangea macrophylla leaves according to the weight ratio of the medicinal materials to ethanol solution of 1:20, soaking for 24 hours, heating, refluxing and extracting for 3 times, wherein the extracting time is 3h, 3h and 3h, respectively, combining three extracting solutions, filtering, recovering a solvent, concentrating until the relative density is 1.00-1.20, extracting the concentrated solution for three times respectively by using petroleum ether and n-butyl alcohol, extracting according to the weight ratio of the concentrated solution to the solvent of 1:1, combining three n-butyl alcohol extracting solutions, concentrating to obtain 167g of n-butyl alcohol extract, dissolving the n-butyl alcohol extract with distilled water 2.0L, filtering, adsorbing the filtrate to a 3kg D101 type macroporous resin column for three times, repeatedly adsorbing for the first time, eluting with distilled water with 6 times of column volume and 20% ethanol solution with 6 times of column volume, eluting with 40% ethanol solution with 10 times of column volume, collecting 40% ethanol eluent with 40% of column volume, concentrating to obtain 10.6g of total phenolic acid extract of total phenolic acid content of the hydrangea macrophylla total phenolic acid extract.
Example preparation of Total phenolic acid extract of Sibaxian flower leaves (four)
Adding 70% ethanol into 2kg of dried hydrangea macrophylla leaf extract which is crushed according to the weight ratio of the medicinal material to ethanol solution of 1:8 for soaking for 12 hours, then heating and refluxing for 2 times, wherein the extraction time is 3h, 2h and 2h respectively, combining three extraction solutions, filtering, recovering a solvent, concentrating until the relative density is 1.00-1.20, extracting the concentrated solution with petroleum ether and n-butyl alcohol respectively for three times, extracting according to the weight ratio of the concentrated solution to the solvent of 1:1, combining three n-butyl alcohol extraction solutions, concentrating to obtain n-butyl alcohol extract of 68.9g, dissolving the n-butyl alcohol extract with distilled water of 3.5L, filtering, adsorbing the filtrate with an HPD400 type macroporous resin column of 4kg for three times, eluting with distilled water of 3 times of the column volume and 10% ethanol solution of 4 times of the column volume for the first time, collecting 30% ethanol elution solution of 30% and concentrating to obtain the total phenolic acid content of the hydrangea macrophylla total phenolic acid extract of 2.3 g.
Example inhibition of in vitro proliferation of human medullary thyroid carcinoma cells by Total phenolic acid extract from leaves of hydrangea macrophylla
1 × 104The inhibition of cell proliferation by total phenolic acid extract from hydrangea macrophylla is calculated by the following formula:
cell proliferation inhibition ratio (%) - (OD)Blank control well-ODTotal phenolic acid extract of hydrangea macrophylla)/ODBlank control well×100％
The result is shown in figure 1, and the total phenolic acid extract of hydrangea macrophylla can inhibit the proliferation of human medullary thyroid cancer cell lines, the inhibition effect is dose-dependent and time-dependent, and the IC50 of the total phenolic acid extract of hydrangea macrophylla within 48 hours on the proliferation of medullary thyroid cancer cells is 4.14mg/m L.
Example six in vivo pharmacodynamic experiments to study the inhibition of Total phenolic acid extract from hydrangea macrophylla to growth of medullary carcinoma of thyroid tumor in mice
100 mu L cells were inoculated into the right anterior axillary space of 6-week-old, female Balb/c nude mice until tumors grew to 100mm3On the left and right, 30 nude mice were randomly divided into 5 groups, namely a blank control group, a positive (doxorubicin) control group and high-low (2000, 1000 and 500mg/kg) dose groups of total phenolic acid extract of hydrangea macrophylla. The total phenolic acid extract from hydrangea macrophylla treated group (500, 200 and 100mg/kg) was gavaged once a day with 200 μ l of physiological saline solution containing different concentrations of total phenolic acid extract from hydrangea macrophylla dissolved in 2.5% Tween-80 and 2.5% ethanol for 18 days of continuous treatment. The blank control group was given an equivalent volume of saline, while the positive control group was administered doxorubicin at a dose of 5mg/kg every four days in tail vein. Tumor volumes were measured every two days,the calculation formula is as follows: v (mm)3) Pi/6 × is × long and × wide.
FIGS. 2 to 4 show the effect of the total phenolic acid extract from hydrangea macrophylla on the growth of medullary thyroid carcinoma, and FIGS. 2 to 4 show the effect of the total phenolic acid extract from hydrangea macrophylla on the growth of medullary thyroid carcinoma, the effect on the body weight of mice, and the effect on the tumor growth of mice, respectively. The results show that: in a transplantation model of subcutaneous tumor of human medullary thyroid carcinoma cell line, the total phenolic acid extract of hydrangea macrophylla has dosage-dependent anti-tumor effect on medullary thyroid carcinoma tumor. The tumor inhibition rates of the total phenolic acid extract of the hydrangea macrophylla leaves of 100mg/kg, 200mg/kg and 500mg/kg on medullary thyroid carcinoma tumors are 64.14%, 72.47% and 74.58% respectively.
Claims (12)
1. The preparation method of the hydrangea leaf extract is characterized by comprising the following steps: the method comprises the following steps:
(1) pulverizing dried folium hydrangeae strigosae, soaking in ethanol water solution, and heating for extraction;
(2) filtering to obtain filtrate, concentrating, and keeping the concentrated solution;
(3) extracting the concentrated solution obtained in the step (2) with petroleum ether or n-hexane, then extracting with n-butanol, concentrating the n-butanol layer extract under reduced pressure to obtain extract, adding water to dissolve the extract, and performing suction filtration to obtain filtrate for later use;
(4) adsorbing the filtrate obtained in the step (3) by using a macroporous resin column, sequentially eluting by using distilled water, 10% v/v-20% v/v ethanol water solution, 20% v/v-30% v/v ethanol and 30% v/v-40% v/v ethanol, collecting 30% v/v-40% v/v ethanol eluate, concentrating, drying, crushing and sieving to obtain the hydrangea leaf extract.
2. The method for preparing hydrangea macrophylla leaf extract according to claim 1, comprising: the concentration of the ethanol aqueous solution in the step (1) is 60-90%, the material-liquid ratio is 1:5-20 by weight, the soaking time is 12-24 hours, and the heating reflux extraction is carried out for 2-3 times, and each time lasts for 2-3 hours.
3. The method for preparing hydrangea macrophylla leaf extract according to claim 1, comprising: and (3) concentrating the mixture in the step (2) until the relative density is 1.00-1.20.
4. The method for preparing hydrangea macrophylla leaf extract according to claim 1, comprising: and (3) extracting the concentrated solution with petroleum ether and n-butanol for 2-3 times respectively, wherein the dosage of the organic solvent adopted in each extraction is 0.5-1:1 of the weight ratio of the concentrated solution to the organic solvent, the n-butanol extract is dissolved by adding water, and the extract is dissolved by adding distilled water according to the weight ratio of the extract to the distilled water of 1: 10-35.
5. The method for preparing hydrangea macrophylla leaf extract according to claim 1, comprising: and (3) extracting the concentrated solution for 3 times by using petroleum ether and n-butanol respectively, wherein the dosage of an organic solvent adopted in each extraction is 1:1 of the weight ratio of the concentrated solution to the organic solvent, the n-butanol extract is dissolved by adding water, and the extract is dissolved by adding distilled water according to the weight ratio of the extract to the distilled water of 1: 10-35.
6. The method for preparing hydrangea macrophylla leaf extract according to claim 1, comprising: at least one of the following is satisfied:
the macroporous resin column in the step (4) is AB-8, HPD300, HPD400 or D101 type macroporous adsorption resin;
in the step (4), 3-6 column volumes are eluted by distilled water, 3-6 column volumes are eluted by 10% v/v-20% v/v ethanol water solution, and 3-10 column volumes are eluted by 30% v/v-40% v/v ethanol;
loading the sample in the step (4), and loading the sample into a macroporous resin column according to the weight ratio of the medicinal materials to the resin of 1: 1-2;
the elution speed of the elution in the step (4) is 0.1-0.5L/h.
7. The hydrangea leaf extract prepared by the method of any one of claims 1 to 6.
8. The hydrangea leaf extract according to claim 7, characterized in that: the total phenolic acid content in the extract is more than 40%.
9. Use of the hydrangea macrophylla extract according to claim 7 or 8 for the preparation of a medicament for the treatment of thyroid cancer.
10. A pharmaceutical composition characterized by: the medicine is prepared by taking the hydrangea macrophylla extract as the main active ingredient and adding pharmaceutically conventional auxiliary materials into the hydrangea macrophylla extract as the main active ingredient, wherein the extract is defined in claim 7 or 8.
11. The pharmaceutical composition of claim 10, wherein: the medicament is an oral preparation or an injection preparation.
12. The pharmaceutical composition of claim 11, wherein: the oral preparation is tablet, capsule, granule, or oral liquid; the injection preparation is an intravenous injection preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710448481.6A CN107213176B (en) | 2017-06-14 | 2017-06-14 | Hydrangea macrophylla leaf extract, and pharmaceutical composition, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710448481.6A CN107213176B (en) | 2017-06-14 | 2017-06-14 | Hydrangea macrophylla leaf extract, and pharmaceutical composition, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107213176A CN107213176A (en) | 2017-09-29 |
| CN107213176B true CN107213176B (en) | 2020-07-28 |
Family
ID=59948491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710448481.6A Active CN107213176B (en) | 2017-06-14 | 2017-06-14 | Hydrangea macrophylla leaf extract, and pharmaceutical composition, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107213176B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110776581B (en) * | 2019-12-03 | 2022-01-14 | 赵顺英 | Hydrangea macrophylla polysaccharide and application thereof in treating myocardial ischemia reperfusion injury |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102319291A (en) * | 2011-08-19 | 2012-01-18 | 大连中植环境生物科技有限公司 | A kind of leaf of Broussonetia papyrifera (L.) L.Her.ex Vent. total phenolic acid extract and the application in the preparation cancer therapy drug thereof |
| CN103599148A (en) * | 2013-11-15 | 2014-02-26 | 沈阳药科大学 | Agriophyllum squarrosum total flavonoid extract, and preparation method and application thereof |
-
2017
- 2017-06-14 CN CN201710448481.6A patent/CN107213176B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102319291A (en) * | 2011-08-19 | 2012-01-18 | 大连中植环境生物科技有限公司 | A kind of leaf of Broussonetia papyrifera (L.) L.Her.ex Vent. total phenolic acid extract and the application in the preparation cancer therapy drug thereof |
| CN103599148A (en) * | 2013-11-15 | 2014-02-26 | 沈阳药科大学 | Agriophyllum squarrosum total flavonoid extract, and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 八仙花叶正丁醇层化学成分研究;程娜等;《山地农业生物学报》;20131231;第32卷(第3期);第251-253页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107213176A (en) | 2017-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103494875B (en) | Application of cyclocarya paliurus extract in preparation of medicament for preventing and treating leukemia | |
| CN112870236B (en) | Flavone effective part of abelmoschus manihot and preparation method and application thereof | |
| CN102370695B (en) | Qinglongyi active extract, its preparation method and its application | |
| CN107213176B (en) | Hydrangea macrophylla leaf extract, and pharmaceutical composition, preparation method and application thereof | |
| CN101028322B (en) | Use of Maoliefengdou extract for preparing anti-cancer medicine | |
| CN104983814A (en) | Pulsatilla chinensis extract and application thereof to preparation of drugs for preventing and treating pulmonary fibrosis | |
| CN106883306A (en) | A kind of extraction separation method of the sunflower stem core polysaccharide with antitumor activity | |
| CN101396373B (en) | Cinobufacini extract and preparation method thereof | |
| CN107753531B (en) | Wenwang-herba violae extract and application thereof in preparing anti-cancer drugs | |
| CN101411779B (en) | Chinese medicine effective component composition for treating liver cancer and method for preparing the same | |
| CN103191143B (en) | New application of cardiac glycoside compound | |
| CN1806831B (en) | Medicine for treating psoriasis and its preparing process | |
| CN107095893B (en) | Extraction method and application of active substances of panax pseudoginseng | |
| CN102688248A (en) | Use of bufadienolide compound in preparing medicines for treating oral mucosal malignant tumors | |
| CN108721532B (en) | For assisting in the treatment of the Chinese medicine composition of lung cancer | |
| CN106727892A (en) | A kind of compound taxol preparation and preparation method thereof | |
| CN102351934B (en) | Steroidal alkaloid compounds and pharmaceutical composition thereof, as well as preparation methods and applications of steroidal alkaloid compounds and pharmaceutical composition of compounds | |
| CN100427099C (en) | Juglans mandshurica maxim pdysaccharide preparation capable of effectively treating brain cancer and its preapring method | |
| CN104840747B (en) | Chinese medicine composition with antithyroid cancer activity and its preparation method and application | |
| CN104398532B (en) | Application of cardiac glycoside compound 12beta-hydroxycalotropin | |
| CN102805768A (en) | Application of catclaw buttercup root extract to preparation of anti-lung cancer medicines | |
| CN102988525A (en) | Preparation method for total lignans in hawthorn seeds, and novel application | |
| CN102008599B (en) | Girald daphne bark leaf extract and medicinal application thereof | |
| CN110279751B (en) | Pharmaceutical composition for treating gastric cancer | |
| CN101181336A (en) | Method for refining valid target of bitter gourd for dropping blood sugar |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |